THE Pharmaceutical Benefits Advisory Committee (PBAC) has supported a platform recommendation for current and future Pfizer Cominarty COVID vaccines to be NIP-listed after TGA approval.
The vaccine is recommended for use in adults aged 75 years or more (two doses per year); adults aged 65-74 years (one dose per year); adults aged 18-64 years with severe immunocompromise (one dose per year); and Aboriginal and Torres Strait Islander adults aged 50-74 years (one dose per year).
During its Dec meeting, PBAC also recommended the PBS listing of seladelpar for the treatment of primary billary cholangitis (PBC).
The committee noted the medication was found to be as effective as obeticholic acid (OCA) at reducing markers of liver damage and improving cholestasis, with similar safety, while also improving itching symptoms and promoting lower rates of PBCrelated pruritus than patients treated with OCA.
PBAC also recommended amending the PBS listing for hydroxychloroquine sulfate 200mg tablets - which are commonly prescribed for autoimmune conditions - to increase the maximum number of repeats per prescription from one to three.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 26
